October 22-24, 2024 | Boston, MA
www.til-therapies.com

ONSITE AGENDA

6th Annual

TIL Therapies Summit

Enhance TIL Function & Manufacturing to Expand Treatment Benefit Beyond Melanoma

Advancing Next Generation Engineering, Clinical Strategy & Scale-Up Innovations to Further Accelerate the Next Wave of TIL Therapies to Market

Expert Speakers Include:

James Yang
Senior Investigator
Steven Rosenberg Group, National Institute of Health

Yarong Liu
Chief Executive Officer
GRIT Biotechnology

Friedrich Finckenstein
Chief Medical Officer
Iovance

Micah Benson
Chief Medical Officer
KSQ Therapeutics

Gary Lee
Chief Scientific Officer
Lyell Immunopharma

Madan Jagasia
Chief Executive Officer
Obsidian Therapeutics

Proud to Partner with:

ScaleReady
Miltenyi Biotec
bio SHARING network
CTMC+
NANOTEIN TECHNOLOGIES
DISCOVERY LIFE SCIENCES
ThermoFisher SCIENTIFIC
ENRICH BIOSYSTEMS
SONY

+1 617 455 4188 info@hansonwade.com
www.til-therapies.com Cell Immunotherapy
hansonwade

Pre-Conference Workshop Day
Tuesday, October 22

Registration & Morning Coffee — 8.15

Workshop A — 9.00 - 12.00

Enhancing Potency Assays for TIL: Unlocking Precision & Reliability for Regulatory Approval

With the regulatory approval of Lifileucel and more candidates preparing for commercialization, gaining clarity on effective potency assays to streamline regulatory approval is now at the forefront.

Join this workshop to:

- Explore how to select and establish potency assays to demonstrate product efficacy
- Understand how to adapt potency assays to different stages of the clinical development in cell therapies
- Gain clarity on regulatory requirements for next generation engineered TILs
- Evaluate requirements of specific and non-specific potency assays when meeting regulatory standards
- Gain insights into solutions in managing low viability tumor cell lines when developing assays for challenging indications

Workshop Leaders

Violetta Medik
Associate Director of Analytical Development
KSQ Therapeutics

Divya Lenkala
Group Leader
T-Cell Immunology
BioNTech

Lunch Break & Networking — 12.00

Workshop B — 1.00 - 4.00

Overcoming Neoantigen Screening Bottlenecks & Empowering Predictions for Expansion of Neoantigen Reactive TILs

Many TIL developers face bottlenecks in screening for neoantigens and predicting immunogenicity and selectivity potential of discovered neoantigens, which exasperates manufacturing timelines. This workshop discusses solutions and current advancements to expedite processes, crucial for advancing TIL therapy development amidst burgeoning demand.

Join this workshop to:

- Discuss the challenge of intratumor heterogeneity and tools for targeting clonal neoantigens which are present on every tumour cell
- Explore state-of-the-art bioinformatics tools to accelerate isolation of potentially immunogenic neoantigens
- Evaluate tools to screen for challenging antigens such as MHC class 2 neoantigens
- Dive deep into the development of assays for predicting the selectivity and immunogenicity of neoantigens, including assay design and validation methodologies
- Engage in technical discussions on the challenges and limitations associated with current approaches in neoantigen screening and prediction
- Consider the ability to overcome immune evasion mechanisms through neoantigen selection

Workshop Leaders

Sergio Quezada
Chief Scientific Officer
Achilles Therapeutics

James Yang
Senior Investigator
Steven Rosenberg Group
National Institute of Health

Conference Day One
Wednesday, October 23

7.20 Registration & Coffee

Markus Maeurer
Professor
Champalimaud Foundation

8:20 **Chair's Opening Remarks**

Diving into Current Opportunities & Excitement in the TIL Field for Future Expansion

8.30 **Industry Leaders Fireside Chat: Challenges & Opportunities in Expanding Beyond Melanoma**

An interactive panel discussion from the industry leaders of the field to set the scene on the TIL therapy space. Ask your questions live to understand the expert's thoughts on key topics including:

- What is the current state on developing TILs for indications beyond melanoma?
- What are key hurdles that must be overcome to apply TILs to more diverse indications?
- How do we evaluate what indications are most suitable to target with TILs?
- What are some key opportunities and breakthroughs in applying TILs to uncharted indications?

Micah Benson
Chief Scientific Officer
KSQ Therapeutics

Yarong Liu
Chief Executive Officer
GRIT Biotechnology

Friedrich Finckenstein
Chief Medical Officer
Iovance

Madan Jagasia
Chief Executive Officer
Obsidian Therapeutics

Tony Pnewski
G-Rex Optimization Specialist
ScaleReady

9.20 **G-Rex® Grant Program: For the Advancement of CGT Development and Manufacturing**

Sean Hall
Director of Research
Iovance

9.30 **Next-Gen TIL: Counteracting the Solid Tumor Microenvironment**

- Targeting immune checkpoint targets using gene editing
- Developing tethered cytokine approaches to increase TIL persistence post-infusion
- Enhancing tumor-specific immunity through enrichment and selection

10.00 **Morning Refreshment Break & Speed Networking**

As the TIL community is reunited, this valuable session will ensure you can reconnect with your peers in the room to make new and lasting connections. Also, don't forget to enjoy some refreshments before we split off into the two different tracks: Preclinical & Translation, Clinical Strategy & Manufacturing

Preclinical & Translation

Track Chair: Cecilia Zhang, Co-Founder & Chief Scientific Officer, **Biosyngen**

Clinical Strategy & Manufacturing

Track Chair: Ignacio Nunez, Chief Operations Officer, **CellReady**

Designing Next Generation TIL Products for Enhanced Potency

11.00 eTIL: Enhancing Anti-Tumor Function through CRISPR/Cas9 Gene Editing

- Immune CRISPRomics Platform discovered SOCS1 and Regnase-1 as top gene targets enhancing T-cell anti-tumor function
- KSQ-001EX and KSQ-004EX are single and dual-edited engineered TIL (eTIL) products with inactivation of SOCS1 and Regnase-1

Micah Benson, Chief Scientific Officer, **KSQ Therapeutics**

Novel Understanding & Approaches to Simulating Neoantigen Reactive T-Cells for an Effective & Prolonged Response

11.00 Targeting Clonal Neoantigens with Precision T-Cell Therapies: Key Mechanistic Insights From cNeT Clinical Trials

Unique translational science platform enables us to track the active component of TIL (clonal neoantigen reactive T-cell) in patients and determine key mechanisms underpinning *in vivo* activity

Key insights to date include:

- Impact of host conditioning in T-cell persistence and engraftment
- Critical role of evasion mechanisms (such as HLA loss) in resistance to T-cell based therapies

Sergio Quezada, Chief Scientific Officer, **Achilles Therapeutics**

Conference Day One
Wednesday, October 23

11.30 Using Intracellular Checkpoint Knockout TILs for Increased Reactivity

- First in-human clinical data on engineered TILs
- Knockout of CISH checkpoint for TCR avidity

Branden Moriarity, Professor, **University of Minnesota**

11.30 CTMC Tech Stack: Integrated Solutions to Develop Better TIL

- Progressing next generation TIL therapies rapidly through clinical testing via a co-development model
- Innovating next generation TIL process and analytical development/manufacturing/regulatory/clinical working in concert with partners to advance the development of promising TIL therapies to quickly reach patients
- Committing to provide solutions or improvements to TIL process/product robustness through integration or development of enabling technologies
- Establishing workflows with MD Anderson Cancer Center to ensure rapid trial start-up and execution of data-rich clinical studies

Chantale Bernatchez, Head of Process Development, **CTMC**

12.00 Roundtable Discussion: Highlighting Key TIL Genetic Targets Amenable for Engineering Enhanced TILs

- Discussing which TIL genes may be of interest to amend for desired characteristics.
- What makes a TIL gene a good target for modification?
- What are some of the most common TIL genes being modified and what makes them good targets?

Branden Moriarity, Professor, **University of Minnesota**

Cecilia Zhang, Co-Founder & Chief Scientific Officer, **Biosyngen**

12.00 Clinical & Translational Learnings of BNT-221, a Neoantigen-Specific Adoptive T-Cell Therapy & Next Steps for Future Product Iterations

- An insight into NEO-STIM and its applications: our process to prime, activate and expand neoantigen specific T-cells
- An overview of clinical safety and efficacy results of BNT221 and deep characterization of the generated drug products and peripheral samples
- An outlook of what is next including process improvements and product enhancements

Marit van Buuren, Senior Director T-Cell Immunology & Process Development, **BioNTech**

12.30 Lunch

1.30 The Discovery & Development of Next-Generation Long-Lasting Anti-Exhaustion TIL Therapies

- Design and development of function and persistence enhanced GT2 series TIL products engineered by StaViral® virus platform
- Development of GT3 series TIL products by CRISPR KO of potent immunoregulatory targets identified through ImmuT Finder®, a genome-wide CRISPR/Cas9 screening platform
- Preliminary safety and efficacy of next-gen TIL products in human trial as monotherapy in advanced solid tumors

Jingwei Sun, Director of Early Discovery, **GRIT Biotechnology**

Strategies for Enriching Tumor Reactive T-Cells to Maximize Manufacturing TIL Count

1.30 Cutting-Edge MSE™-TIL Platform for Enhanced Anti-Tumor Efficacy with Broader Clinical Applications

- Introduction of the company and the background
- Unique features of Biosyngen's MSETM-TIL platform
- Efficient *ex vivo* expansion from tumor biopsy samples
- Efficient genetic modification system
- Pre-clinical data on anti-tumor efficacy of the MSETM-TIL system

Cecilia Zhang, Co-Founder & Chief Scientific Officer, **Biosyngen**

Leveraging Resources Between Industry & Academia to Accelerate TIL Discovery

2.00 Roundtable Discussion: Aligning Industry & Academic Establishments to Accelerate TIL Discovery

- Increasing access to tissue samples, clinical and real-life data to empower R&D efforts
- Evaluating key opportunities in partnerships between clinical institutions and industry
- Discussing hurdles in academia and industry to the spread of data and publishing of results to advance shared knowledge of TILs

Pranav Murthy, Senior Scientist, **Adicet Bio**

Eduardo Davila, Co-Founder & Chief Scientific Officer, **Trampoline Pharma**

2.00 Unveiling Novel Approaches to Expanding Tumor-Reactive T-Cells & Reducing Bystander T-Cells

- Sorting CD8 TIL for CD39 and CD103 prior to expansion enhances for tumor reactivity
- This selected expanded TIL has clinical activity in late-stage cancer patients

Andrew Weinberg, Chief Scientific Officer, **AgonOx**

2.30 Afternoon Break & Poster Session

Conference Day One
Wednesday, October 23

Improving Patient Outcomes & Toxicity of TIL Therapies by Reducing IL2 Burden

Madan Jagasia
Chief Executive Officer
Obsidian Therapeutics

3.30 **Rational Engineering of TIL with Membrane-Bound IL15 to Optimize Expansion, Persistence, Safety, & Efficacy of TIL Cell Therapy for Solid Tumors**

- Evaluating the design of T-cells to utilize IL15
- Key advantages of membrane bound IL15 over IL2
- Clinical data on effects of IL15 and its safety characterization

Ian R. Hardy
Director Preclinical & Translational T Cell Therapy
Miltenyi Biotec B.V. & Co. KG

4.00 **Clinical-scale selection & expansion of GBM tumor-reactive T cells using the CliniMACS Prodigy TRT Process**

- CliniMACS Prodigy TRT system is a GMP compliant TIL manufacturing platform
- Automated CD137+ selection and enrichment of GBM-TRTs at clinical scale
- CD137+ selected GBM-TRTs have significantly enhanced tumor reactivity

Yi Zhao
Chief Executive Officer & Chief Technology Officer
Sino-Cell Biomed

4.30 **Optimizing Manufacture Culture Conditions to Reduce Dependence on IL2 *In Vivo***

- Reduced IL-2 in culture system
- Target production time 16 days
- Significantly less IL-2 after TIL infusion and TCR data show TIL repopulation *in vivo*

Eduardo Davila
Co-Founder & Chief Scientific Officer
Trampoline Pharma

5.00 **Lowering TCR & IL2 Receptor Activation Threshold**

- Importance of reducing or eliminating IL2 for TIL therapy
- Mechanisms that lower the activation threshold activation threshold of gamma common chain signaling enhance T-cell persistence while reducing toxicity

5:30 **Closing Remarks**

5:40 **Drinks Reception**

"It was excellent to see how the TIL manufacturing space has evolved in a few years and unite with friends and colleagues. Very good opportunity to do networking"

Associate Director, **Nurix Therapeutics**, Past Attendee

Conference Day Two
Thursday, October 24

7.45 Morning Coffee

Markus Maeurer
Professor
Champalimaud Foundation

8.25 **Chairs Opening Remarks**

Improving Clarity & Synchronization of Efforts for Successful Development & Commercialization of TILs

8.30 **Panel Discussion: Key Considerations for Increasing TIL Treatment Capacity & Preparing for Commercialization**

- What are key steps to increase TIL infrastructure and meet patient demand?
- Considerations such as TIL treatment facilities, staff recruitment and training, and resources
- What are the model regulatory and reimbursement strategies for TILs?
- Navigating the current regulatory landscape and discussing key considerations when preparing for commercialization

Chair:

Janet Lynch Lambert
Advisor
Alliance for Regenerative Medicine

Yang Liu
Vice President
China Credit Enhancement Corporation

Eduardo Davila
Co-Founder & Chief Scientific Officer
Trampoline Pharma

Rodabe Amaria
Professor
MD Anderson Cancer Center

Ignacio Nunez
Chief Operations Officer
CellReady

Nicholas Restifo
Co-Founder & Chief Scientist
Marble Therapeutics

9.15 **Key Qualities of TILs & Hallmarks of Successfully Developing TIL Therapies**

- Highlighting advantages of TIL poly-clonality and state-of-the-art approaches such as AI/ML to obtain and preserve truly tumor reactive T-cells
- Identifying gene-modifications to enhance TIL expansion, persistence, and efficacy
- Discussing current innovations in cell culture methods for effective TIL expansion

Hem Sapkota
Director
Biosharing Network

9.45 **Presentation by Biosharing Network**

- Discuss how feeder cells can be made from a byproduct of plateletpheresis procedures
- Discuss the advantages of an off-the-shelf feeder cell product
- Discuss product configurations of an off-the-shelf feeder cell product

10.15 Morning Refreshment Break & Networking

Preclinical & Translation

Track Chair: Cecilia Zhang, Co-Founder & Chief Scientific Officer, **Biosyngen**

Equipping TILs with Necessary Modifications to Persist in Immunosuppressive Tumor Microenvironments

11.00 **Rejuvenation of T-Cells Results in Younger Epigenetic Age & Improved Anti-Tumor Functions *In Vitro* & *In Vivo***

- Novel potential disruptive technology to rejuvenate T-cells across multiple therapeutic modalities
- Rejuvenated T-cells show younger epigenetic age, enhanced cell proliferation and cytokine release, and sustained antitumor activity *in vitro* and *in vivo*
- Rejuvenated TILs preserve polyclonal anti-tumor TCR repertoire and display improved antitumor properties

Gary Lee, Chief Scientific Officer, **Lyell Immunopharma**

Clinical Strategy & Manufacturing

Track Chair: Ignacio Nunez, Chief Operations Officer, **CellReady**

Advancing Sample Collection Methods to Set Manufacturing Up for Success

11.00 **Optimizing Starting Material Quality through Targeted Sample Collection**

- What are some approaches we can take to increase the proportion of tumor reactive T-cells in starting material?
- Exploring imaging techniques to identify biologically and clinically relevant tumor areas as a starting material for TIL
- Determining the quality of antigen-specific T-cell responses associated with the original location in the starting tissue material

Markus Maeurer, Professor, **Champalimaud Foundation**

Conference Day Two
Thursday, October 24

11.30 Utilizing CoSTAR Cells for Persistent Activity in the Tumor Microenvironment

- Tumor reactive T-cells become dysfunctional within the tumor microenvironment (TME), where little co-stimulation is present
- Provision of co-stimulation in the TME by genetic modification of TIL with CoStAR® restores T-cell function *in vitro* and improves anti-tumor efficacy in pre-clinical models

Mark Dudley, Chief Scientific Officer, **Instil Bio**

11.30 Circulating Tumor Reactive T-Cells (cTRLs) - Characteristics & Novel Approach to Isolation

- Utilizing IsoQore technology for effective isolation of cTRLs from blood as a means of non-invasive sample collection
- Key characteristics and advantages of cTRLs

Derrell Porter, Chief Executive Officer, **CTRL Therapeutics**

12.00 Counteracting T-Cell Exhaustion: T-Cell Therapy Meets Organelle Medicine

- Bone marrow stromal cells transfer mitochondria to CD8+ T cells via intercellular nanotube connections.
- Mitochondrial transfer augments CD8+ T cell metabolic fitness.
- Mitochondrial transfer empowers TCR and CAR-modified T cells as well as TILs to counteract exhaustion and fight tumors more effectively.

Luca Gattinoni, Professor, **Leibniz Institute for Immunotherapy**

Harvesting the Wealth of TILs: Navigating the Commercial Landscape

12.00 From Bedside to Bankside: Exploring the Commercial Potential of TIL as a Therapeutic Pillar

- Commercial positioning of TIL in I/O
- Key strategies to ensure TILs are commercially viable for developers
- Opportunities for biotech companies to leverage their technology for licensing

Yang Liu, Vice President, **China Credit Enhancement Corporation**

12.30 Lunch Break & Networking

1.30 Reverting TIL Exhaustion to Generate a TIL Product with More Stemness-Like T-Cells & a Broader T-Cell Repertoire to Improve Clinical Outcome

- Mapping T-cell specificities against tumor associated and HPV-derived antigens in TIL therapy products in cervical cancer
- Key strategies for *ex vivo* enrichment of tumor-reactive TILs including reinvigorating exhausted TILs and selective expansion
- Arming T-cells against oxidative stress preserving killing functionality in the hostile tumor microenvironment

Ulrik Cordes, Chief Executive Officer, **Cbio**

Understanding of Adverse Events for Improved Patient Treatment & Clinical Retention

1.30 Patient Selection & Adverse Event Management for Solid Tumor TIL Therapy

- Criteria for appropriate patient selection
- Considerations for bridging therapy
- Identification and management of treatment-related adverse events

Rodabe Amaria, Professor, **MD Anderson Cancer Center**

Conference Day Two
Thursday, October 24

2.00 Engineering Tumor-Targeting T-Cells to Overcome the Tolerance Barriers in Cancer Treatment

- Exploring genetic-enhancing modifiers (GEMs) as a platform to modify TIL function and the TME
- Enhancing TIL killing and persistence in the TME through modulation

Eric Chen, Founder & Chief Scientific Officer, **Achelois Biopharma**

2.00 Panel Discussion: Evaluating Current Treatment Procedures to Identify Gaps & Opportunities in Treatment Protocols

- Evaluating the need for lymphodepletion and other pre-treatment protocols
- How do we determine timing and order of treatment procedures when prioritizing the patient?
- How do treatment protocols differ between different patients?

Nicholas Restifo, Co-Founder & Chief Scientist, **Marble Therapeutics**

Markus Maeurer, Professor, **Champalimaud Foundation**

Rodabe Amaria, Professor, **MD Anderson Cancer Center**

George Coukos, Director of Oncology, **Ludwig Institute for Cancer Research**

2.30 Afternoon Break & Refreshments

Boosting Understanding of TIL & Solid Tumor Mechanisms to Develop an Effective TIL Product

Andrea Aran
Researcher
Hospital Clinic Barcelona

3.30 Optimizing Different Cell Populations for an Effective TIL Product

- Evaluating important differences between cell types such as CD4+ and CD8+ T-cells for a well-rounded TIL effective product
- How can we select different cell types and ensure consistent long-term maintenance and proliferation?
- What is the role of dendritic cells in TIL Therapy products?

Pranav Murthy
Senior Scientist
Adicet Bio

4.00 Leveraging the Unique Strengths of Gamma Delta T cells to Treat Patients with Solid Tumors

- γδ1 T cells preferentially traffic to solid tissues and are positive prognostic indicators of improved survival in patients with cancer.
- γδ T cells combine innate and adaptive mechanisms to recognize and kill malignant cells.
- Superior tumor specific reactivity of γδ cell therapies compared to αβ references.

George Coukos
Director, Oncology
Ludwig Institute for Cancer Research

4.30 Understanding of TIL Mechanisms for Successful Targeting of Potent T-Cells

- Understanding the tumor microenvironment of origin that impacts the quality of T-cell product
- Understanding the molecular ingredients of TIL product potency
- Understanding the state dynamics of T-cells upon expansion and transfer
- Enhancing TIL product potency by selectively enriching for tumor specific T-cells

5.00 Closing Remarks

5.10 End of Conference

"It was very helpful to me. It was great to be able to gain a lot of useful information from other companies' data and experience"

Team Manager, **Neogene Therapeutics**, Past Attendee

Proud to Partner With

LEAD PARTNER

Scale Ready

ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf. Bringing together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing, ScaleReady provides leading therapeutic developers with the most simple, scalable, and versatile manufacturing platform in the industry. Our platform includes G-Rex® cell culture technology, the Lovo and Cue cell processing systems, and a wide range of GMP proteins, reagents, media, and gene editing technologies.

www.scaleready.com

EXPERTISE PARTNERS

Miltenyi Biotec B.V. & Co. KG

Miltenyi Biotec B.V. & Co. KG is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative technologies enable solutions for cellular research, cell therapy, and cell manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec B.V. & Co. KG has more than 4,700 employees in 23 countries.

www.miltenyi.com

Biosharing Network

The market's most experienced provider of IRRADIATED APHERESIS DERIVED FEEDER CELLS, the BioSharing Network is a partnership between eight US blood centers. The network has over two million donors and has decades of experience recruiting donors and performing apheresis procedures. Our network provides GMP (mobilized & non-mobilized) leukopacks, bone marrow, cord blood and perinatal tissue, as well as providing support services including flowcytometry, cryopreservation and prodigy-based manufacturing. With multiple donor rooms, clean rooms for manufacturing, and strong logistics teams, we are the most reliable provider in the market.

www.biosharingnetwork.com

PROGRAM PARTNER

CTMC

CTMC – a joint venture between MD Anderson Cancer Center and Resilience – was created to accelerate the development and manufacturing of impactful cell therapies for patients with cancer. Our strategic position within the Texas Medical Center, combined with our expertise in TIL and CAR-T development, manufacturing, and regulatory, converge to enable an accelerated path to IND for cell therapies. By leveraging the strengths of MD Anderson and Resilience we start clinical trials faster and provide a clear path to robust commercialization.

www.ctmc.com

Proud to Partner With

EXHIBITION PARTNER

Nanotein Technologies

Nanotein Technologies is a Berkely-based, Series-A biotechnology start-up manufacturing next generation reagents for expansion and activation of immune cells for Cell Therapy applications. Our technology is a fully soluble, protein scaffold with specific functional antibodies bound with a high-affinity linkage to the protein core. This creates a highly effective protein-antibody product, for targeted and robust activation - taking advantage of receptor clustering biology for maximum impact. On the market today, we sell products for T cell and NK cell (feeder free!) activation and expansion.

We're a technical and collaborative team - small, but mighty - and would love for our reagents to help your cell therapy manufacturing process. We love to chat with potential customers, learn about your processes and help you optimize your workflows with our reagents. Send us a message or pick up some product to get started today!

www.nanoteintech.com

Enrich Biosystems Inc.

Enrich Biosystems Inc. is a life science tool company focusing on developing and commercializing a unique microfluidics-free cell discovery and isolation technology.

Enrich's novel cell discovery platform, TROVO, enables a streamlined workflow of co-culturing, kinetics profiling, and image guided cell capturing based on cell behavior and function. Enrich team partners with world-class research institutions to develop critical applications for its platform, such as therapeutic T-cell discovery, tumor sample processing, and patient cancer cell line generation. Its non-fluidics, dissolvable microwells, and visual enrichment enable large-scale, low-cost, and high-precision cell-based biomedical discovery; providing a needed alternative to existing microfluidics-based, limited throughput , and expensive current technologies.

Enrich's TROVO system has successfully been utilized at leading academic and top 10 biopharma institutes to identify and isolate highly valuable tumor-reactive T cells from a heterogeneous pool of candidates. The isolated T cells from TROVO are amenable to sequencing for identification or can be expanded for utilization in animal studies.

www.enrichbio.com

EVENT PARTNER

Discovery Life Sciences

Discovery Life Sciences is a leading provider of highly characterized human biospecimens and cellular starting materials integrated with expert multi-omic analytical services to advance cell and gene therapy and precision medicine programs for cancer, infectious disease, and other complex conditions. Our AllCells® RUO and GMP products have supported many complex cell and gene therapy programs transition seamlessly from early discovery to process development and manufacturing, with an average 98% collection deliverability rate.

www.allcells.com

Thermo Fisher Scientific

As the world leader in serving science, Thermo Fisher Scientific is uniquely positioned to provide the quality materials, services and support needed to accelerate the pace of cell and gene therapy development. We understand the complexity of this rapidly evolving industry and have made significant investments in cGMP raw material manufacturing and drug product manufacturing capabilities to provide innovative workflow solutions. Partner with us to access the high-quality materials, services, and support you need from discovery to clinical research and commercial cell and gene manufacturing. Through our Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab services, Patheon, and Gibco brands, we offer an unmatched combination of innovative technologies, manufacturing, and distribution capabilities.

www.thermofisher.com

Sony Biotechnology Inc.

Sony Biotechnology Inc. is dedicated to helping researchers working across different life science disciplines to achieve the best scientific results. By leveraging Sony's vast know-how in electronics innovation and design we offer next-generation cell analysis systems to accelerate your discoveries. Our goal is to bring a unique perspective to the flow cytometry tools required for in-depth single cell isolation, analysis and cell sorting. With our core expertise in automation and software development we hope to enable discovery research across immunology, oncology, cell biology and microbiology.

www.sonybiotechnology.com

Notes

+1 617 455 4188 info@hansonwade.com
www.til-therapies.com Cell Immunotherapy

hansonwade

Notes